Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport
Contact Us
Search
Close

COVID-19 Update: Omicron Variant Specifics

By Yvonne Puig (US), Daphne Calderon (US) & Hannah Putnam (US) on December 30, 2021
Email this postTweet this postLike this postShare this post on LinkedIn

Since its first detection, the Omicron variant of COVID-19 has been reported in numerous countries worldwide and in most of the United States. It is likely more transmissible than the other variants of COVID-19 and has officially surpassed the Delta variant contraction rates. As of December 25, 2021, the CDC reported the Omicron variant represents almost 60% of the reported cases of COVID-19 as compared to the Delta variant’s roughly 40% of cases. Today alone, the US reported a record of 282,000 new diagnosed cases.

On December 28, 2021, the FDA announced its observations from a preliminary study of the Omicron variant related to testing and detection. The FDA has been working with the National Institutes of Health’s (NIH) RADx program to study the Omicron variant and how to best track whether a person has contracted it. The study indicated that antigen diagnostic tests are effective for virus detection but may have reduced sensitivity. Specifically, the antigen tests “are less likely to pick up very early infections compared to molecular tests.”

According to some news outlets, the Omicron variant has particularly affected children. ABC reported a “five-fold increase in pediatric admission in New York City” in December and “[c]lose to double the numbers admitted in Washington, D.C.” Likewise, ABC reported that about 260 children in the United States are being admitted to hospitals each data, “and nearly 2,000 children are currently hospitalized with the virus.” UPI reported similar findings, explaining that child hospitalizations are up 30% in the last week as the Omicron variant continues to spread.

Notwithstanding these statistics, the CDC updated its guidelines for quarantining and recommends a shortened time for isolation for the public: “People with COVID-19 should isolate for 5 days and if they are asymptomatic or their symptoms are resolving (without fever for 24 hours), follow that by 5 days of wearing a mask when around others to minimize the risk of infecting people they encounter.” According to the CDC, this condensed timeframe for recommended isolation is due to studies indicating transmission occurs early in the course of the illness.  CDC Director Dr. Rochelle Walensky stated, “Prevention is our best option: get vaccinated, get boosted, wear a mask in public indoor settings in areas of substantial and high community transmission, and take a test before you gather.”

Norton Rose Fulbright lawyers will continue to provide relevant updates for healthcare providers on the Health Law Pulse during the COVID-19 public health crisis.

Photo of Yvonne Puig (US) Yvonne Puig (US)

US Head of Life Sciences and Healthcare Yvonne Puig has a substantial commercial litigation practice in both state and federal courts. She represents hospitals, HMOs, managed care organizations, medical schools and other institutional health care providers and educational services companies. A partner in…

US Head of Life Sciences and Healthcare Yvonne Puig has a substantial commercial litigation practice in both state and federal courts. She represents hospitals, HMOs, managed care organizations, medical schools and other institutional health care providers and educational services companies. A partner in Norton Rose Fulbright’s Austin office, Yvonne’s practice involves commercial and health care litigation, antitrust, regulatory and compliance advice, crisis management, staff privileges, exclusive contracting and administrative law.

Read more about Yvonne Puig (US)Email
Show more Show less
Photo of Daphne Calderon (US) Daphne Calderon (US)
Read more about Daphne Calderon (US)Email
Photo of Hannah Putnam (US) Hannah Putnam (US)
Read more about Hannah Putnam (US)Email
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    Health Law Pulse
  • Organization:
    Norton Rose Fulbright
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
  • About LexBlog
  • The Field We Built
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo